Kusajili – Clinical trials directory

Result of your search per sponsor: Pascal HAMMEL, MD

Woman and Man Max 99 years
Pascal HAMMEL, MD Update Il y a 4 ans

A Study of Sunitinib Versus Placebo in Combination With Lanreotide in Patients With Progressive Advanced/Metastatic Midgut Carcinoid Tumors Sunitinib may provide an opportunity for a novel therapeutic strategy for the treatment of subjects with neuroendocrine tumors.

Country Belgium, France
organs None
Specialty None

Closed trial

More information